2020年10月13日 · Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of prod- uct candidates engineered to cross the BBB for neurodegenerative diseases.

2021年10月26日 · Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers …

2022年2月22日 · Secarna's ASOs combined with Denali's BBB transport delivery technology offer the potential to provide truly novel therapies to people living with a wide range of difficult-to …

2021年10月26日 · Denali will apply its blood-brain barrier (BBB) Transport Vehicle (TV) technology to enable delivery of these LNAplus TM -based ASOs to the central nervous …

2022年2月22日 · Under the collaboration, Secarna is employing its LNAplus TM platform to generate ASO candidates against targets relevant for the treatment of neurodegenerative …

2021年10月26日 · MUNICH/MARTINSRIED, GERMANY / ACCESSWIRE / October 26, 2021 / Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), a biopharmaceutical company …

2020年10月13日 · Under this agreement, the companies will leverage Secarna's LNAplus TM ASO discovery platform - the only independent next generation ASO platform - and Denali's …

2022年2月22日 · Secarna Pharmaceuticals GmbH & Co. KG today announced that Denali Therapeutics Inc. (“Denali”) has exercised its option to in-license an ASO program generated …

2021年10月26日 · Secarna Pharmaceuticals GmbH & Co. KG, a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide …

2020年10月13日 · Under this agreement, the companies will leverage Secarna's LNAplus TM ASO discovery platform - the only independent next generation ASO platform - and Denali's …